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Abstract: We have developed a computational framework for spatiotemporal integration of 
molecular and anatomical datasets in a virtual reality environment. Using two case studies 
involving gene expression data and pharmacokinetic data, respectively, we demonstrate how 
existing knowledge bases for molecular data can be semantically mapped onto a standardized 
anatomical context of human body. Our data mapping methodology uses ontological representa-
tions of heterogeneous biomedical datasets and an ontology reasoner to create complex semantic 
descriptions of biomedical processes. This framework provides a means to systematically 
combine an increasing amount of biomedical imaging and numerical data into spatiotempo-
rally coherent graphical representations. Our work enables medical researchers with different 
expertise to simulate complex phenomena visually and to develop insights through the use of 
shared data, thus paving the way for pathological inference, developmental pattern discovery 
and biomedical hypothesis testing.
Keywords: anatomical atlas, gene expression, pharmacokinetics, biomedical data integration, 
CAVEman, virtual reality in medicine
Introduction
Biomedical data produced while studying an organism using a number of lab techniques 
often exist in a wide variety of data formats, which are often incompatible with each 
other. The spatial granularity of such data can vary greatly, from the molecular level 
(eg, models of elucidated molecular complexes) to the macroscopic level (eg, volu-
metric scans of tissues and organs).1 Existing integration techniques for multi-database 
systems, data warehousing and federated database systems2 are often inadequate for 
handling the abundance of biomedical data, because of the diversity, complexity, and 
the ever-changing nature of the biomedical data sources. Most biomedical data sources, 
such as genome sequences, proteomics data, metabolomic information, and anatomi-
cal data, are created and managed independently, presenting a number of challenges 
when data from multiple sources need to be integrated in order to create a solution to 
complex biomedical queries.
We have created an integrated ontology-based framework that enables semantic 
interoperability between multiple autonomous biomedical data sources with differ-
ent semantics. Using two case studies, one involving gene expression data and the 
other using pharmacokinetic data, we describe how the framework combines a set of 
molecular data with an anatomical atlas of 3D human body. Our source of anatomi-
cal data is the CAVEman project (http://www.4dbioinformatics.ca), which provides 
a standardized anatomical context for the exploration of biomedical datasets in a 
virtual reality environment using an object-oriented model of the human body. The 
anatomical component of CAVEman3 is based on the 3D digital atlas of the human International Journal of Nanomedicine 2009:4 80
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adult male anatomy developed by Kasterstener Inc, expanded 
from its earlier version,4 which is structured according to the 
nomenclature deﬁ  ned in Terminologia Anatomica.5,6
Integration framework
The goal of our integration framework is to enable the user 
to visualize an integrated representation of biomedical data 
coming from separate data sources (Figure 1). The platform 
for this integration is the human body atlas of the CAVEman 
system. The user queries a biomedical data source for a subset 
of data to be visualized. The data query interface formats 
the user query depending on the type of the data to retrieve 
the desired instances of data. The data is then partitioned 
into anatomical information (eg, body systems or organs) 
and symbolic information (eg, numbers or positive/negative 
indicators), which are separately mapped for subsequent 
integration. The semantic mapper ﬁ  nds the mapping from the 
components of anatomical information to standardized terms 
or IDs adopted in the human body atlas. This process generates 
a set of unique indices for the relevant three-dimensional (3D) 
graphic models of the anatomical objects. The visual mapper 
produces a graphic representation of the symbolic information 
to be viewed, using selected visual features such as color, 
shape, and texture. Symbolic information is converted to a 
set of visually salient features that also represents the original 
information unambiguously. In a virtual reality environment, 
renderings of the visual features on the selected models of the 
human body atlas are generated and presented to the user.
Semantic mapping is required because there are a wide vari-
ety of different anatomical terminologies used in biomedical 
data sources.7 Nonstandard terms referring to organs and tissues 
need to be mapped to standardized identiﬁ  ers for the anatomical 
parts of interest. The actual methods of ﬁ  nding the semantic 
mapping vary according to the type of data. Visual mapping 
is employed to convert symbolic (ie, textual and numerical) 
information to visual features that can be represented unam-
biguously in a virtual reality environment. The selection of 
the speciﬁ  c visual features to be used is guided by the ranges 
of values to represent and the methods used for normalizing 
them. We achieve the integration in 3D space by combining 
semantic mapping and visual mapping. If the data to be visual-
ized is time-dependent, spatiotemporal mapping is obtained by 
repeatedly applying this spatial mapping framework over the 
existing time points. We show the applicability of this generic 
framework to integrating different types of data sources with 
the human body anatomical atlas by using two case studies.
Case study 1: Gene expression 
data mapping
The problem
Our ﬁ  rst case study is on integration of genomic and anatomi-
cal data, which involves visual mapping of gene expression 
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Figure 1 A computational framework for spatial integration of molecular and anatomical data. The anatomical information contained in the molecular data is semantically 
mapped to indices to a human body atlas. The textual or numerical information is mapped to visual features to be rendered on the retrieved 3D models of the human body 
in a virtual reality environment.International Journal of Nanomedicine 2009:4 81
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data onto the anatomical context provided by the human 
body atlas. The amount of gene expression information 
generated from microarray experiments has been grow-
ing at an exponential rate.8 As those experiments employ 
high-throughput methods, a tremendous amount of data 
is created even from a single experiment. While statistical 
analysis of gene expression data can reveal interesting pat-
terns, presenting the analysis results in a visually intuitive 
way should also be an essential part of any gene expression 
analysis program. The visual aspect of dataset presentation 
is a signiﬁ  cant factor that provides intuitive insights into 
patterns and leads to conclusions, which might be missed 
when using only statistical assessments.
Most software for gene expression data analysis performs 
unsupervised clustering to generate meaningful groups of 
genes without bias of prior knowledge of gene function. 
However, the high dimensionality of the datasets often 
hinders the discovery of interesting patterns, clusters, and 
outliers, making it difﬁ  cult to classify genes into meaningful 
groups automatically. Researchers often have to refer to many 
kinds of speciﬁ  c genomic and anatomical information while 
maintaining an overall view of the gene expression dataset, 
in order to make sense of the analysis results even if they are 
visually presented (eg, heat maps). Visual mapping of gene 
expression values onto a highly relevant context, such as the 
tissues themselves from which mRNA expression values 
were experimentally measured, would provide the user a 
coherent view of the vast array of the expression values. To 
this end, a system for gene expression proﬁ  ling should be able 
to integrate as much biologically and statistically relevant 
information as possible and provide the user with a coherent 
simultaneous view of such pieces of information.
The data
The gene expression data has been retrieved from Genomics 
Institute of the Novartis Research Foundation (GNF) 
SymAtlas,9 a publicly available database of gene function 
and structure (http://symatlas.gnf.org). In particular, we use 
the Human U133A/GNF1H microarray dataset, which has 
been pre-normalized using the GC content adjusted Robust 
Multi-array Average (gcRMA) algorithm.10 The dataset 
contains gene expression values for 44,760 probe sets in 
79 human organs and tissues, obtained using Affymetrix probe 
set identiﬁ  ers.11
Methods
We applied the integration framework of Figure 1 to integrate 
gene expression data with anatomical data. The implementations 
of the semantic mapper and visual mapper are dictated by 
the characteristics of the gene expression data we wanted to 
visualize. Figure 2 illustrates the methods and the data ﬂ  ow 
for gene expression data mapping, which is based on the 
integration framework.
The semantic mapper implementation is based on ontolo-
gies, which formalize vocabularies deﬁ  ned by data own-
ers, their properties, and their semantic relationships and 
restrictions within a knowledge domain.12,13 We use the Web 
Ontology Language (OWL; http://www.w3.org/2004/owl) to 
establish semantic relationships among entities from separate 
biomedical datasets. For each data source, an OWL ontology 
generator creates a local ontology that describes the data 
source, and translates the data into instances of the newly cre-
ated ontology. The data owners then deﬁ  ne the relationships 
between the elements of the newly generated ontology and 
the semantic constructs from other related ontologies.
For our case study, we use two local ontologies in the 
form of OWL resources. The ﬁ  rst one represents the GNF 
SymAtlas dataset that lists the available genes, the tissues 
in which their expression were measured, and the cor-
responding microarray spot intensity values (SymAtlas 
ontology). This ontology contains 44,760 terms describ-
ing the genes, where each gene term contains 79 terms 
describing spot intensity values from different organs and 
tissues. The second one describes the tissue names used in 
GNF SymAtlas and their mapping to the standard Termi-
nologia Anatomica terms (tissues ontology). This ontology 
contains 79 terms, as it only describes the mapping from 
the anatomical terms for the organs and tissues used in the 
dataset to proper TA IDs. The mapping is sometimes not 
straightforward, as the SymAtlas anatomical terms are not 
always directly mappable to a TA term. Thus, the actual 
mapping was done not by the providers of the SymAtlas 
data, but by the researchers for this case study. We have 
modiﬁ  ed the Pellet reasoning engine14 to validate semantic 
relationships between ontologies automatically. The map-
ping from a gene ID to tissue names to TA IDs is automatic 
due to the use of this ontology reasoner.
The semantic mapper starts with a search for the instances 
the Affymetrix ID of a queried gene in the SymAtlas ontology. 
Genes are referred to by the corresponding Affymetrix probe 
set identiﬁ  ers: for example, 1007_s_at is the Affymetrix probe 
set ID of a human epithelial discoidin domain-containing 
receptor 1 precursor gene. The data available for this gene 
is contained within the affymetrix:gene_1007_s_at element 
of the SymAtlas ontology ﬁ  le. Once matching records are 
found in the OWL-formatted data, the associated information, International Journal of Nanomedicine 2009:4 82
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including terms that describe the cell line or tissue in which 
the expression was measured and the spot intensities of such 
measurements as recorded in the SymAtlas data source, is 
retrieved. The tissue ontology is used for relating tissue 
names used in the SymAtlas data to the corresponding TA 
identiﬁ  ers. For example, “Heart” in SymAtlas data is mapped 
to the TA ID of “A12.1.00.001.”
The role of the visual mapper is to convert the retrieved 
numerical gene expression values into visual features that can 
be readily rendered on the human body atlas. We chose to use 
color as the key visual feature because it can represent a vast 
range of expression values. The gene expression values are 
ﬁ  rst normalized with respect to a control or reference organ 
that can be selected by the user. In the case study, any one 
of the 79 organs can be chosen as the control organ. Thus an 
expression value that is greater than that for the control organ 
would be regarded as over-expressed. Using a neutral color 
for the control organ (eg, white) the expression values for 
all the other organs are color-mapped to show the strength 
of the gene expression in the corresponding organs, relative 
to the control organ. This provision is useful comparing the 
relative expression levels of a gene in many different organs 
simultaneously.
Results
The visualization result for the Affymetrix ID 1007_s_at is 
shown in Figure 3. It clearly shows very high expression of 
the gene in the amygdala and the colorectal adenocarcinoma 
cell lines (mapped onto the 3D rectum model); relatively 
high expression in olfactory bulbs, the pituitary gland and 
the trachea; relatively low expression in cerebral peduncles, 
kidneys, pancreas, pons and tongue tissues; and low expres-
sion in the heart and liver tissues. In contrast to the original 
numerical dataset, which contains a rather overwhelming 
amount of data (79 spot intensity values in different tissues 
for each probe set), our 3D visualization gives the user an 
immediate, easy-to-comprehend visual summary of the high-
lights of the body-wide expression patterns. With this type 
of visualization, there is no need for the user to mentally link 
a multitude of expression values to a collection of tissues in 
which each value was measured from. The measuring con-
text and the magnitude of the expression values are clearly 
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Figure 2 Semantic mapping and visual mapping for integrated visualization of gene expression data for a queried gene.   The semantic mapper maps anatomical terms to organ 
IDs in TA using the ontologies. The visual mapper normalizes gene expression values with respect to a control organ and converts them into color values to be used for 
rendering the organs.International Journal of Nanomedicine 2009:4 83
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represented as the anatomical organs displayed and their 
color, respectively. This helps to alert the human explorer 
visually to the presence of “interesting” patterns in the data, 
which can be explored further using the original dataset.
Case study 2: Pharmacokinetic 
data integration
The problem
Our second case study involves a knowledge base provided 
by the Human Metabolome project,15 in particular its 
DrugBank component.16 The goal of the case study is to 
visually model the absorption, distribution, metabolism, 
and excretion (ADME) of drugs within the anatomical 
context. Almost every FDA approved drug must go through 
rigorous pharmacokinetic analysis, wherein the drug’s 
ADME is determined through a combination of animal 
experiments and computer modeling. Therefore, creating 
a mechanism for accurate ADME models and simulations 
has the potential to contribute to the drug discovery and 
design processes.
One of the difﬁ  culties in pharmaceutical metabolomics 
is that there is a signiﬁ  cant disconnect between the experi-
mental data (which is often visually represented) and the 
pharmacokinetic models (which are nonvisual). In particular, 
pharmacokinetic modeling is largely done using simpliﬁ  ed 
Figure 3 3D visualization of body-wide gene expression patterns for the Affymetrix probe ID 1007_s_at, shown for 12 selected organs. Darker shades of red represent 
higher expression values.International Journal of Nanomedicine 2009:4 84
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compartmental models (boxes with different partition 
coefﬁ  cients), based on classical differential equations with 
simpliﬁ  ed boundary conditions. This approach may appeal to 
mathematicians but not necessarily to biologists or medical 
doctors who are involved in drug development and testing. 
Likewise, classical methods mostly ignore the importance 
of visualization as an aid to understanding pharmacokinetic 
or metabolic processes. Spatiotemporal mapping of pharma-
cokinetic events onto their proper anatomical context will 
allow drug developers to: (i) share their results with a broader 
audience; (ii) assist in teaching pharmacokinetic principles to 
students and clinicians; (iii) permit real-time exploration and 
testing of drug ADME; and (iv) better integrate experimental 
data with theoretical calculations.
The data
The data was generated using a Java program for ADME 
modeling, called ADME-Modeler, developed in the 
Human Metabolome project (http://metabolomics.ca). The 
software interactively requests the following information 
from the user: (i) the chemical compounds involved in the 
ADME reactions; (ii) route of administration (enteral/oral 
or parenteral/intravenous), volume of distribution, and 
bioavailability; (iii) the rate constants of absorption, dis-
tribution, conversion and elimination for each compound; 
and (iv) additional information such as time intervals and 
dosage regimen. The program then calculates the temporal 
distribution, concentration and location of each of the drugs 
and drug metabolites using either the ﬁ  rst-order elimination 
or the Michaelis–Menten kinetics17 as selected by the user. 
To calculate compound concentrations in different organs, 
the human body is conceptually divided into three com-
partments: (i) the gastric-intestinal compartment including 
the stomach and the intestine; (ii) the central compartment 
including highly perfused organs such as the cardiovascular 
system, liver, kidney, brain, spleen, and lungs; and (iii) the 
peripheral compartment including cerebrospinal ﬂ  uid, bone, 
muscle, and adipose tissue.
ADME and pharmacokinetic information on several drugs 
were obtained: acetaminophen (Tylenol), acetylsalicylic acid 
(Aspirin), atorvastatin (Lipitor), ﬂ  uoxetin (Prozac), and silde-
naﬁ  l (Viagra). The information was compiled from multiple 
sources after an extensive literature search. For example, 
the search revealed that ingested acetylsalicylic acid (ASA) 
is converted to salicylic acid (SA) within the stomach and 
the circulation system.18 SA is then either renally excreted 
or ﬁ  rst converted to one of four known derivatives (salicyl 
acyl glucuronide, gentisic acid, salicyl phenolic glucuronide, 
or salicyluric acid) before subsequent renal excretion.19,20 
The rates of absorption of ASA and SA from the stomach, 
the rates of conversion from one compound to another, and 
the rates of excretion of the various ASA derivatives are 
shown in Figure 4, which were all identiﬁ  ed from the relevant 
literature.18,21–23
The constants and modeling formulas, such as those indi-
cated for ASA, were used to automatically produce the con-
centration data for the compounds in various compartments 
over time, resulting in a time series for each compound and 
each compartment affected. Thus the ADME data for a drug 
takes the form of a two-dimensional matrix of concentrations 
(eg, in milligrams), where each row corresponds to a distinct 
time instant and each column represents a compartment in 
which the concentrations were measured.
Methods
The integration of pharmacokinetic data with anatomical 
data is accomplished by applying the integration framework 
shown in Figure 1. The two core tasks of the framework that 
need to be implemented in a data-dependent way are the 
semantic mapping and the visual mapping. The workings of 
these two components are illustrated in Figure 5.
The anatomical information contained in the ADME 
data of a drug is given in terms of compartments in which 
the metabolite measurements were taken, and therefore is 
different from Terminologia Anatomica (TA), on which the 
organization of the human body atlas is based. These terms 
can be retrieved from the header of the ADME data ﬁ  le and 
fed to a compartment-to-organ mapper that maps each com-
partment to corresponding standardized organ names and TA 
identiﬁ  ers. For example, the ‘Blood’ compartment will be 
mapped to the organ ‘A12.0.00.000’ (cardiovascular system) 
in TA, which determines that the chemical compounds 
located in the blood will be shown on the cardiovascular sys-
tem of the atlas. The use of ontological representation was not 
needed for this mapping, as the number of terms involved did 
not warrant the added complexity. However, as the number 
of compartments and the number of corresponding organs 
grow, it will eventually be necessary to adopt ontologies.
The visual mapper needs to produce visual features for 
expressing different chemical compounds and their concen-
trations contained in the ADME data. We chose to use colors 
and their intensities to represent the compounds and their 
concentrations. First, unique base colors (eg, red, green, or 
blue) are assigned to each chemical compound (or a small 
group of a few compounds if their behaviors are similar) 
appearing in the data. Then the color of an organ at a given International Journal of Nanomedicine 2009:4 85
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Figure 4 The ADME ﬂ  ow of acetylsalicylic acid in three anatomical systems, corresponding to the initial ingestion, blood concentration, and urine concentration. Either the ﬁ  rst 
order elimination or the Michaelis-Menten kinetics with the speciﬁ  ed parameters is used for modeling changes over time in chemical compounds themselves, in concentration, 
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Figure 5 Semantic mapping and visual mapping for integrated visualization of pharmacokinetic data for a single time point. The ADME data is given as a matrix where each cell 
represents the numerical concentration value of a chemical compound existing in an organ at a time instant. The semantic mapper maps compartments to organ IDs in TA. 
The visual mapper converts each concentration value to a color value and combines them into a mixed color for each organ.International Journal of Nanomedicine 2009:4 86
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time is calculated by scaling the base color of the compound 
existing in that organ at that time instant by its relative 
concentration, such that darker colors stand for heavier con-
centrations. If multiple compounds exist simultaneously in an 
organ at a certain time point, the colors depicting the different 
compounds are mixed to indicate the mixture of compounds. 
This process effectively converts a numerical concentration 
value of a compound into a unique color value representing 
the compound and its concentration as well.
Results
The semantic mapper and visual mapper illustrated in Figure 5 
accomplish the core part of the pharmacokinetic data mapping. 
The mapping results are visualized within the virtual reality 
environment offered by the CAVEman system. After the 
desired anatomical systems are loaded into the visualization 
scene, the user loads the text ﬁ  le that contains the ADME data of 
a particular drug, which triggers the series of mapping processes 
required for visual integration of the data. Figure 6 illustrates 
the interface for the loading of acetaminophen (Tylenol) ADME 
data into the visualization system. This particular data has 
11 (compound, organ) pairs after compartment-to-organ map-
ping was performed, over 1001 discrete time instants, resulting 
in a total of 11,011 concentrations to visualize. Currently loaded 
anatomical models are displayed in the left panel according to 
the TA hierarchy, with those affected by the drug shown in 
red. By selecting an anatomical organ or system, the user can 
see the list of the chemical compounds that exist in the model 
at some time points on the right. The bottom panel controls 
the visualization parameters such as the base colors to assign 
to compounds and the time steps for playing the animation of 
the ADME process.
The spatiotemporal visualization shows the dynamically 
changing mixture of colors in the selected body compartments 
to illustrate the ADME process. Figure 7 shows three typical 
snapshots of the ADME visualization using 3D models of the 
Figure 6 Graphical user interface for the visualization of the acetaminophen ADME process.International Journal of Nanomedicine 2009:4 87
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stomach, small intestine, arterial structures and kidneys. The 
original drug compound (red) is shown to be ﬁ  rst absorbed 
through the digestive organs. Simultaneously with its absorp-
tion into the blood stream, it is metabolized into derivative 
compounds (green), which are distributed throughout the 
body. Eventually all compounds are eliminated from the blood 
and are excreted through the urinary system. The mixture of 
red and green color components for each organ is dynamically 
updated to animate the time series values in the ADME data. 
This way of visual representation eliminates the need for the 
user to mentally keep track of multiple concentrations existing 
in multiple organs over a period of time, which essentially 
forms a three-dimensional matrix of concentration values, to 
make sense of the ADME data.
Our integration framework is successful in producing the 
pharmacokinetic data visualization results to guide researchers 
through a complex set of numerical data, and allow scientists 
of various backgrounds to share insights, which normally could 
only be grasped by a few specialists. The anatomical context is 
quite important as a communication vehicle within the medical 
community, as it can be presumed to be part of the background 
knowledge of everyone involved in the respective study.
Discussion
Our framework is unique in that it combines semantic mapping 
and visual mapping into an integrated visualization of the bio-
medical data at hand. There were studies on biomedical data 
integration that mostly focused on lexical and semantic mapping 
of data elements contained in a biomedical database to another 
database by combining schema-based and instance-based 
approaches7 or using an ontology processing tool.24 While our 
case studies utilize only two independent data sources at a given 
time (ie, anatomical plus genomic datasets or anatomical plus 
metabolomic datasets), the integration framework is generic 
enough to accommodate a larger number of data sources, as 
long as they are semantically related and can be mapped directly 
or represented by interrelated ontologies. Examples of such data 
sources are multiple gene expression datasets, metabolomic 
datasets, and medical imaging datasets.
To our knowledge, comparable work on visually inte-
grating anatomical data and other types of biomedical data 
is scarce. BioMediator25 is a data integration system that has 
been applied to link four heterogeneous neurophysical data 
sources for the needs of neuroscience researchers. Although it 
uses the Foundational Model of Anatomy (FMA) ontology,26 
there is no visual component that puts the integrated data in 
an anatomical perspective. FMA has also been used as the 
central anatomical ontology for integrating the Gene Ontology 
(GO; http://www.geneontology.org) and the Mouse Genome 
Informatics (http://www.informatics.jax.org).27 This work is 
similar to ours in that it used anatomy as a hub for combining 
different genomic knowledge sources, but FMA only func-
tions as an information portal for browsing and querying. For 
example, there is no visualization of gene expression values 
in the anatomical context.
Our work demonstrates that converting biomedical data 
into ontologies, as we have done for the SymAtlas gene 
expression dataset, provides a number of technological 
beneﬁ  ts. The process of transforming ontologies into OWL 
has recently been described from the biological and technical 
perspective.28 An important advantage of OWL encoding is 
that new relationships can be automatically inferred using 
ﬁ  rst-order logic, which is key to minimizing the manual effort 
required in deﬁ  ning relationships between data sources. In 
a) b) c)
Figure 7 Integrated visualization of pharmacokinetics data on 3D human body. Different metabolites are displayed with different shades of color corresponding to 
concentrations: a) initial absorption into the digestive system; b) distribution and metabolism throughout the cardiovascular system; and (c) the elimination and excre-
tion of by-products through the urinary system.International Journal of Nanomedicine 2009:4 88
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contrast, traditional data integration efforts would create 
either a global schema to which all data providers map their 
data or ﬁ  eld mappings between each pair of databases. The 
former diminishes data-provider independence and limits the 
view of the underlying data, whereas the latter introduces 
combinatorial complexity and requires strict lexical identity 
among the data sources to enable queries. Our ontology-based 
semantic mapping facilitates modular architecture in which 
data sources can be completely independent.
The semantic mapping aspect of the integration frame-
work deals mostly with anatomical information, whereas 
the visual mapping module converts the remaining symbolic 
information into a visually meaningful form. The choice 
of visual features is of critical importance, as the features 
should have sufﬁ  cient dimensionalities to be able to repre-
sent the variability in the data values present in the sym-
bolic information, and yet they should be easily rendered 
in the visualization environment. We chose color as the 
main visual feature in both case studies because it has at 
least two visually (as opposed to colorimetrically) distinct 
dimensions: the hue and shade. For example, this choice 
has helped us to successfully render all possible mixtures 
of multiple chemical compound concentrations by using a 
hue to represent a compound itself and different shades to 
represent concentrations.
The importance of knowledge integration has been widely 
understood in the narrower area of bioinformatics, which 
focuses predominantly on molecular studies.29,30 The broader 
ﬁ  eld of nanomedicine presents an even more challenging area 
for data integration: indeed, complex biomedical phenomena 
involve diverse and seemingly unrelated data from several 
domains of knowledge, each of which has already spawned 
a variety of data formats and vastly different scales, from a 
nanoscale to a macroscale. The emphasis on visualization 
as a data integration platform leads to natural development 
of a practical data integration framework where the nature 
of semantic mapping as well as visual mapping is deﬁ  ned 
by the characteristics of the biomedical data sources to be 
integrated.
The importance of our framework lies in presenting a 
methodological template for the visual spatiotemporal model-
ing of molecular events in their proper anatomical context. 
The two case studies demonstrate that this framework, based 
on mapping of data semantics and judicious use of visual 
features, enables spatiotemporal visualization of complex 
biomedical phenomena. 3D graphical representation provides 
users with high-level models that are self-explanatory and 
lead to further investigation into the raw data. Visualization 
of biomedical data in a proper context can help researchers 
to obtain a comprehensive view of the massive complexity 
of multiple incompatible data types and focus instead on 
developing a highly intuitive understanding of the studied 
phenomena. Information visualization has already become 
one of the main techniques in bioinformatics, and we antici-
pate that its importance will only increase.
Conclusions
We have described a systematic framework for bioinformatics 
data integration based on integration of semantic mapping 
and visual mapping results. We use ontologies to seman-
tically (as opposed to lexically) resolve the ambiguities 
stemming from different sets of uncontrolled terminologies. 
Semantic mapping is accomplished by either using a simple 
term mapper or an ontology reasoning engine to process 
semantic relationships contained in the ontologies. Visual 
mapping transforms the textual or numerical data into visu-
ally distinct and intuitive representations that can readily 
be shown in our virtual reality environment. The integrated 
framework provides users with an effective way to exploit, 
analyze, and interact with their data, as well as to potentially 
embed other data analysis tools.
This work is part of the existing CAVEman Human 
Body project, which uses immersive virtual reality visualiza-
tion and animation to represent biomedical data of varying 
granularity, including spatiotemporal processes. The 3D data 
visualization component of the integration framework allows 
researchers to load, view, and interact with data objects 
ranges from molecular complexes to 3D atlases of different 
organisms. As a result of semantic and visual data integration, 
users can take advantage of the CAVEman capabilities to 
explore the related biological data from different data sources 
across different organisms in an integrated visual environ-
ment and perhaps generate new biological insights.
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